Efficacy of nebulized liposomal amphotericin B in treatment of experimental pulmonary aspergillosis.

Abstract

The efficacy of therapeutic aerosolized amphotericin B (AMB) was studied in a steroid-immunosuppressed murine model of invasive pulmonary aspergillosis. Nebulized liposomal AMB can be a valid approach to the treatment of this infection, with subjects showing significantly improved survival relative to that of subjects given intravenous deoxycholate AMB, as well as lower lung weights and pulmonary glucosamine levels.

• Authors: Joan Gavaldà, María-Teresa Martín, Pedro López, Xavier Gomis, José-Luís Ramírez, Dolors Rodríguez, Oscar Len, Yolanda Puigfel, Isabel Ruíz, Albert Pahissa
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 49 Issue 7 Pg. 3028-30 (Jul 2005) ISSN: 0066-4804 [Print] United States
• PMID: 15980392 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antifungal Agents
• Immunosuppressive Agents
• Liposomes
• Steroids
• Amphotericin B

Topics

• Amphotericin B (administration & dosage, therapeutic use)
• Animals
• Antifungal Agents (administration & dosage, therapeutic use)
• Aspergillosis (drug therapy, microbiology)
• Aspergillus fumigatus (drug effects)
• Female
• Humans
• Immunosuppressive Agents
• Liposomes (administration & dosage, therapeutic use)
• Lung Diseases, Fungal (drug therapy, microbiology)
• Nebulizers and Vaporizers
• Rats
• Rats, Wistar
• Steroids
• Treatment Outcome